DE69514342D1 - Modifizierte polypeptide mit erhoehter biologischer aktivitaet - Google Patents

Modifizierte polypeptide mit erhoehter biologischer aktivitaet

Info

Publication number
DE69514342D1
DE69514342D1 DE69514342T DE69514342T DE69514342D1 DE 69514342 D1 DE69514342 D1 DE 69514342D1 DE 69514342 T DE69514342 T DE 69514342T DE 69514342 T DE69514342 T DE 69514342T DE 69514342 D1 DE69514342 D1 DE 69514342D1
Authority
DE
Germany
Prior art keywords
modified polypeptides
biological activity
increased biological
increased
methods
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE69514342T
Other languages
English (en)
Other versions
DE69514342T2 (de
Inventor
J Sytokowski
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Beth Israel Deaconess Medical Center Inc
Original Assignee
New England Deaconess Hospital
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by New England Deaconess Hospital filed Critical New England Deaconess Hospital
Application granted granted Critical
Publication of DE69514342D1 publication Critical patent/DE69514342D1/de
Publication of DE69514342T2 publication Critical patent/DE69514342T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/505—Erythropoietin [EPO]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
DE69514342T 1994-03-22 1995-03-15 Modifizierte polypeptide mit erhoehter biologischer aktivitaet Expired - Fee Related DE69514342T2 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/216,259 US5580853A (en) 1994-03-22 1994-03-22 Modified polypeptides with increased biological activity
PCT/US1995/003242 WO1995025746A1 (en) 1994-03-22 1995-03-15 Modified polypeptides with increased biological activity

Publications (2)

Publication Number Publication Date
DE69514342D1 true DE69514342D1 (de) 2000-02-10
DE69514342T2 DE69514342T2 (de) 2000-11-30

Family

ID=22806382

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69514342T Expired - Fee Related DE69514342T2 (de) 1994-03-22 1995-03-15 Modifizierte polypeptide mit erhoehter biologischer aktivitaet

Country Status (9)

Country Link
US (1) US5580853A (de)
EP (1) EP0751959B1 (de)
AT (1) ATE188486T1 (de)
DE (1) DE69514342T2 (de)
DK (1) DK0751959T3 (de)
ES (1) ES2143620T3 (de)
GR (1) GR3033146T3 (de)
PT (1) PT751959E (de)
WO (1) WO1995025746A1 (de)

Families Citing this family (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6153407A (en) * 1992-07-28 2000-11-28 Beth Israel Deaconess Medical Center Erythropoietin DNA having modified 5' and 3' sequences and its use to prepare EPO therapeutics
US5614184A (en) 1992-07-28 1997-03-25 New England Deaconess Hospital Recombinant human erythropoietin mutants and therapeutic methods employing them
US5919758A (en) * 1994-03-22 1999-07-06 Beth Israel Deaconess Medical Center Modified polypeptides with altered biological activity
US5747446A (en) * 1994-03-22 1998-05-05 Beth Israel Deaconess Medical Center Modified polypeptides with increased biological activity
US5767078A (en) * 1995-06-07 1998-06-16 Johnson; Dana L. Agonist peptide dimers
EP0914094A4 (de) 1996-03-28 2000-03-01 Univ Illinois Materialen und verfahren zur herstellung verbesserter liposomaler mittel
US6242570B1 (en) 1997-07-10 2001-06-05 Beth Israel Deaconess Medical Center Production and use of recombinant protein multimers with increased biological activity
US6165476A (en) * 1997-07-10 2000-12-26 Beth Israel Deaconess Medical Center Fusion proteins with an immunoglobulin hinge region linker
AU8182298A (en) * 1997-07-10 1999-02-08 Beth Israel Deaconess Medical Center Recombinant erythropoietin / immunoglobulin fusion proteins
US6187564B1 (en) * 1997-07-10 2001-02-13 Beth Israel Deaconess Medical Center DNA encoding erythropoietin multimers having modified 5′ and 3′ sequences and its use to prepare EPO therapeutics
US6217886B1 (en) 1997-07-14 2001-04-17 The Board Of Trustees Of The University Of Illinois Materials and methods for making improved micelle compositions
US6605648B1 (en) * 1999-04-06 2003-08-12 Phillips Plastics Corporation Sinterable structures and method
US20090175821A1 (en) * 1999-05-17 2009-07-09 Bridon Dominique P Modified therapeutic peptides with extended half-lives in vivo
US20040266673A1 (en) * 2002-07-31 2004-12-30 Peter Bakis Long lasting natriuretic peptide derivatives
ES2257298T3 (es) * 1999-05-17 2006-08-01 Conjuchem, Inc. Proteccion de peptidos terapeuticos endogenos contra la actividad de la peptidasa a traves de la conjugacion con componentes sanguineos.
PT1180121E (pt) * 1999-05-17 2004-03-31 Conjuchem Inc Peptidos insulinotropicos de longa duracao
US6887470B1 (en) 1999-09-10 2005-05-03 Conjuchem, Inc. Protection of endogenous therapeutic peptides from peptidase activity through conjugation to blood components
US6514500B1 (en) 1999-10-15 2003-02-04 Conjuchem, Inc. Long lasting synthetic glucagon like peptide {GLP-!}
US6849714B1 (en) * 1999-05-17 2005-02-01 Conjuchem, Inc. Protection of endogenous therapeutic peptides from peptidase activity through conjugation to blood components
US7601691B2 (en) * 1999-05-17 2009-10-13 Conjuchem Biotechnologies Inc. Anti-obesity agents
WO2001003737A1 (en) * 1999-07-13 2001-01-18 Bolder Biotechnology Inc. Immunoglobulin fusion proteins
US6706892B1 (en) 1999-09-07 2004-03-16 Conjuchem, Inc. Pulmonary delivery for bioconjugation
US6703480B1 (en) 1999-11-24 2004-03-09 Palani Balu Peptide dimers as agonists of the erythropoientin (EPO) receptor, and associated methods of synthesis and use
CA2423093C (en) 2000-09-25 2013-09-17 Valentis, Inc. Improved system for regulation of transgene expression
EA006484B1 (ru) * 2001-02-02 2005-12-29 Конджачем, Инк. Долгоживущие производные рилизинг-фактора гормона роста
JP4280070B2 (ja) * 2001-02-16 2009-06-17 コンジュケム バイオテクノロジーズ インコーポレイテッド 胃腸疾患および胃腸障害の処置のための長期持続性グルカゴン様ペプチド２（ｇｌｐ−２）
ITMI20011986A1 (it) * 2001-09-25 2003-03-25 San Raffaele Centro Fond Metodo e composizione per l'attivazione di cellule presentanti l'antigene
GB0209896D0 (en) 2002-04-30 2002-06-05 Molmed Spa Conjugate
GB0209893D0 (en) * 2002-04-30 2002-06-05 Molmed Spa Conjugate
AUPS282602A0 (en) 2002-06-07 2002-06-27 Garvan Institute Of Medical Research Method of inhibiting cell proliferation
AU2003263552A1 (en) * 2002-09-09 2004-03-29 Nautilus Biotech Rational evolution of cytokines for higher stability, the cytokines and encoding nucleic acid molecules
TW200510454A (en) 2003-04-15 2005-03-16 Smithkline Beecham Corp Conjugates comprising human IL-18 and substitution mutants thereof
MXPA05012316A (es) * 2003-05-12 2006-04-18 Affymax Inc Peptidos novedosos que se unen al receptor de la eritropoyetina.
WO2004101611A2 (en) * 2003-05-12 2004-11-25 Affymax, Inc. Peptides that bind to the erythropoietin receptor
CA2525399A1 (en) * 2003-05-12 2004-11-25 Affymax, Inc. Novel spacer moiety for poly(ethylene glycol)-modified peptide-based co mpounds
JP2007530440A (ja) * 2003-05-12 2007-11-01 アフィーマックス・インコーポレイテッド 新規ポリ（エチレングリコール）修飾化合物およびその用途
DE602005022239D1 (de) 2004-04-23 2010-08-19 Conjuchem Biotechnologies Inc Festphase zur Verwendung in einem Verfahren zur Reinigung von Albuminkonjugaten
MX2007005777A (es) * 2004-11-11 2007-07-20 Affymax Inc Peptidos novedosos que se unen al receptor de eritropoietina.
WO2006062685A2 (en) * 2004-11-11 2006-06-15 Affymax, Inc. Novel peptides that bind to the erythropoietin receptor
US20090249503A1 (en) * 2004-12-06 2009-10-01 Bolder Biotechnology, Inc. Enzyme conjugates for use as detoxifying agents
WO2006067633A2 (en) * 2004-12-23 2006-06-29 Molmed Spa Conjugation product
CA2597407C (en) * 2005-02-11 2013-09-10 Immunogen, Inc. Process for preparing stable drug conjugates
US20110166319A1 (en) * 2005-02-11 2011-07-07 Immunogen, Inc. Process for preparing purified drug conjugates
US7919461B2 (en) 2005-06-03 2011-04-05 Affymax, Inc. Erythropoietin receptor peptide formulations and uses
US8324159B2 (en) * 2005-06-03 2012-12-04 Affymax, Inc. Erythropoietin receptor peptide formulations and uses
US7550433B2 (en) * 2005-06-03 2009-06-23 Affymax, Inc. Erythropoietin receptor peptide formulations and uses
AU2006283726C1 (en) 2005-08-24 2015-05-07 Immunogen, Inc. Process for preparing maytansinoid antibody conjugates
US8039432B2 (en) 2005-11-09 2011-10-18 Conjuchem, Llc Method of treatment of diabetes and/or obesity with reduced nausea side effect
CN101678079B (zh) 2006-11-28 2013-12-25 韩诺生物制约株式会社 修饰的促红细胞生成素多肽及其治疗用途
US20090099074A1 (en) * 2007-01-10 2009-04-16 Conjuchem Biotechnologies Inc. Modulating food intake
MX349210B (es) 2009-06-03 2017-07-18 Immunogen Inc Métodos de conjugación.
KR20220009505A (ko) 2011-03-29 2022-01-24 이뮤노젠 아이엔씨 일-단계 방법에 의한 메이탄시노이드 항체 접합체의 제조
EP2742064B1 (de) 2011-08-09 2016-07-27 UAB Profarma Derivate aus rekombinanten proteinen, homo-multimere des granulozyten-kolonie-stimulierenden faktors und verfahren zu ihrer herstellung
US10035817B2 (en) 2012-10-04 2018-07-31 Immunogen, Inc. Method of purifying cell-binding agent-cytotoxic agent conjugates with a PVDF membrane

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4258193A (en) * 1978-07-13 1981-03-24 Toyo Jozo Kabushiki Kaisha Disulfide derivatives having S--S exchange reactivity
US4659839A (en) * 1984-10-10 1987-04-21 Mallinckrodt, Inc. Coupling agents for radiolabeled antibody fragments
US4677195A (en) * 1985-01-11 1987-06-30 Genetics Institute, Inc. Method for the purification of erythropoietin and erythropoietin compositions
US4797491A (en) * 1986-03-17 1989-01-10 Cetus Corporation Compound 1-(3-(2-pyridyldithio)propionamido)-12-(5-hydrazidoglutaramido)-4,9-dioxadodecane
US5260421A (en) * 1987-12-21 1993-11-09 Applied Research Systems Ars Holding N.V. Site-directed mutagenesis modified glycoprotein hormones
US4904584A (en) * 1987-12-23 1990-02-27 Genetics Institute, Inc. Site-specific homogeneous modification of polypeptides
US5066490A (en) * 1988-06-01 1991-11-19 The United States Of America As Represented By The Secretary Of The Department Of Health & Human Services Protein crosslinking reagents cleavable within acidified intracellular vesicles
US5241078A (en) * 1988-06-14 1993-08-31 Cetus Oncology Coupling agents and sterically hindered disulfide linked conjugates prepared therefrom
US5024834A (en) * 1988-07-12 1991-06-18 Cetus Corporation Thioether linked immunotoxin conjugates
US5112615A (en) * 1988-08-03 1992-05-12 New England Deaconess Hospital Corporation Soluble hirudin conjugates
US5134071A (en) * 1989-02-06 1992-07-28 State University Of New York Polymerization and copolymerization of proteins
US5157123A (en) * 1989-03-13 1992-10-20 Georgetown University S-(2-thiopyridyl)-l-cysteine, a heterobifunctional crosslinking reagent
US5116944A (en) * 1989-12-29 1992-05-26 Neorx Corporation Conjugates having improved characteristics for in vivo administration

Also Published As

Publication number Publication date
DE69514342T2 (de) 2000-11-30
EP0751959B1 (de) 2000-01-05
GR3033146T3 (en) 2000-08-31
WO1995025746A1 (en) 1995-09-28
ATE188486T1 (de) 2000-01-15
EP0751959A1 (de) 1997-01-08
DK0751959T3 (da) 2000-06-26
ES2143620T3 (es) 2000-05-16
US5580853A (en) 1996-12-03
PT751959E (pt) 2000-06-30

Similar Documents

Publication Publication Date Title
DE69514342D1 (de) Modifizierte polypeptide mit erhoehter biologischer aktivitaet
IT8619338A0 (it) Peptide sintetico ad attivita'interleukina 1 umana.
IT8812558A0 (it) Poltrona per abbronzatura
DE3582183D1 (de) Dns den menschlichen tumornekrosisfaktor kodierend und das menschliche tumornekronisfaktor-polypeptid.
DK14890A (da) Peptider med t-hjaelpercelleaktivitet
ES8500325A1 (es) Procedimiento para la preparacion de proteinas funcionales de uroquinasa humana.
DE3882593D1 (de) Polypeptid und dessen herstellung.
DK267885A (da) Maebel, saasom sidde- eller liggemaebel
DK96787A (da) Human vaevs-plasminogenaktivator
IT8867463A0 (it) Sedia con sedile oscillante
DE58902290D1 (de) Sauerstoffabsorptionsmittel und verwendung desselben.
ES2177625T3 (es) Citoquina cc-1 humana circulante.
DK50987A (da) Polypeptid med plasminogenaktivatorvirkning
DE3886517D1 (de) Menschlicher Prourokinase ähnliches Polypeptid.
DE3853743D1 (de) Rekombinanter menschlicher ADF.
DE68904336T2 (de) Anti-humankrebsproteinkomplexe, deren herstellung und verwendung.
DE59003265D1 (de) Verwendung von nor-verapamil und nor-gallopamil als antiarteriosklerotica.
KR890015933U (ko) 회전의자
DK527287D0 (da) Polypeptid med interleukin-2-aktiviteter
DE68924022D1 (de) Protein mit hemmender Aktivität gegenüber menschlichem Plasmin.
DE3782199D1 (de) Biologisch aktive peptide tan-866.
NO912072L (no) Rekombinante proteiner med adipsin- og komplement-d-aktiviteter.
DE69019581T2 (de) Polypeptid und dieses enthaltende antibaktierelle Präparate.
IT8619477A0 (it) Sostanza ad attivita'nootropa e psicostimolante.
KR850007051U (ko) 요동식 침대의자

Legal Events

Date Code Title Description
8327 Change in the person/name/address of the patent owner

Owner name: BETH ISRAEL DEACONESS MEDICAL CENTER, INC., BOSTON

8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee